Results 81 to 90 of about 6,457 (202)
PLoS ONE, 2012 Dyrk1A phosphorylated multiple proteins in the clathrin-coated vesicle (CCV) preparations obtained from rat brains. Mass spectrometric analysis identified MAP1A, MAP2, AP180, and α- and β-adaptins as the phosphorylated proteins in the CCVs.
Noriko Murakami +4 more
doaj +1 more source
Alzheimer's disease drug development pipeline: 2026
Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.Abstract INTRODUCTION Discovery and development of new therapies for Alzheimer's disease (AD) are urgently needed to address the world's growing population of individuals on the AD pathophysiological continuum. Clinicaltrials.gov is a resource for studying drugs in development for treatment of AD. RESULTS There are currently 158 drugs in 192 AD trials.
Jeffrey L. Cummings +6 more
wiley +1 more source
DAPK1‐Mediated Parkin Inactivation Enhances Neurotoxicity via MITOL‐Dependent Degradation
Journal of Cellular and Molecular Medicine, Volume 30, Issue 7, April 2026.ABSTRACT Parkinson's disease (PD) is characterised by progressive neurodegeneration and is marked by the formation of Lewy bodies, which are intracellular aggregates primarily composed of α‐synuclein. Mitochondrial dysfunction and impaired protein degradation pathways are thought to play critical roles in PD progression, contributing to the loss of ...
Chul Hong Park +2 more
wiley +1 more source
Dual Targeting of Tau Kinases and Autophagy by Abemaciclib Independent of CDK4/6 Inhibition
Advanced Science, Volume 13, Issue 14, 9 March 2026.Abemaciclib rescues cognitive function and attenuates tau pathology in Alzheimer's disease models, but not through its known cancer‐fighting mechanism. This study demonstrates that abemaciclib operates independently of CDK4/6 inhibition, instead directly targeting tau kinases CaMKII and GSK3β while simultaneously promoting autophagic clearance of ...
Jihui Han +9 more
wiley +1 more source
Neurobiology of Disease, 2005 DYRK1A, dual-specificity tyrosine-regulated kinase 1A, maps to human chromosome 21 within the Down syndrome (DS) critical region. Dyrk1 phosphorylates the human microtubule-associated protein tau at Thr212 in vitro, a residue that is phosphorylated in ...
Isidro Ferrer +6 more
doaj +1 more source
Post‐Translational Modifications in Animal Circadian Clocks
Advanced Science, Volume 13, Issue 16, 18 March 2026.Circadian clocks coordinate physiology with daily environmental cycles through conserved transcriptional–translational feedback loops. This review summarizes how post‐translational modifications fine‐tune clock function, highlights the evolutionary convergence of circadian timekeeping in Drosophila and mammals, and emphasizes the central of these ...
Xianhui Liu, Yong Zhang
wiley +1 more source
Treatment of Dyrk1A-dependent Mental Retardation of Down Syndrome: Isolation of Human Dyrk1A-specific shRNA [PDF]
Journal of Life Science, 2009 Down syndrome (DS) results from overexpressed genes on an extra copy of human chromosome 21. Among various phenotypes seen in DS patients, mental retardation, such as learning and memory deficits, is a major factor that prevents DS individuals from leading fully independent lives.
openaire +1 more source
MedComm – Future Medicine, Volume 5, Issue 1, March 2026.The DYRK family, a pivotal metabolic homeostasis regulator, mediates crosstalk between metabolic disorders and CKD via subtype‐specific mechanisms: DYRK1A drives diabetic (CKD risk), DYRK1B exacerbates metabolic renal injury, DYRK2 contributes to renal osteodystrophy, while DYRK3/4 remain unelucidated.
Yixuan Zhu +9 more
wiley +1 more source
DYRK1A: A master regulatory protein controlling brain growth
Neurobiology of Disease, 2012 Copy number variation in a small region of chromosome 21 containing DYRK1A produces morphological and cognitive alterations in human. In mouse models, haploinsufficiency results in microcephaly, and a human DYRK1A gain-of-function model (three alleles ...
Fayçal Guedj +10 more
doaj +1 more source
Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery
MedComm – Oncology, Volume 5, Issue 1, March 2026.This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem +9 more
wiley +1 more source